Stryker (NYSE:SYK) Lowered to “Hold” Rating by StockNews.com

Stryker (NYSE:SYK) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

Several other equities analysts have also recently issued reports on the company. Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Citigroup raised their target price on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. BTIG Research raised their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Stifel Nicolaus lifted their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Trading Up 0.3 %

Shares of NYSE SYK opened at $391.54 on Tuesday. Stryker has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $379.42 and a two-hundred day moving average of $370.37. The company has a market cap of $149.40 billion, a PE ratio of 50.46, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business posted $3.46 EPS. As a group, equities analysts expect that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in SYK. Assenagon Asset Management S.A. lifted its position in Stryker by 15.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock worth $3,722,000 after buying an additional 1,392 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of Stryker by 23.0% in the third quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock valued at $265,000 after acquiring an additional 137 shares during the last quarter. J.W. Cole Advisors Inc. raised its holdings in Stryker by 23.4% during the third quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock worth $1,420,000 after acquiring an additional 746 shares in the last quarter. Autumn Glory Partners LLC boosted its position in Stryker by 139.8% during the third quarter. Autumn Glory Partners LLC now owns 2,038 shares of the medical technology company’s stock valued at $737,000 after purchasing an additional 1,188 shares during the last quarter. Finally, Old Port Advisors boosted its position in Stryker by 5.2% during the third quarter. Old Port Advisors now owns 934 shares of the medical technology company’s stock valued at $337,000 after purchasing an additional 46 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.